Starget Pharma
Rehovot, Israel· Est.
AI‑powered peptide radiopharmaceuticals for targeted cancer therapy.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered peptide radiopharmaceuticals for targeted cancer therapy.
Oncology
Technology Platform
AI‑driven peptide backbone dynamics platform that simulates and optimizes 3‑D peptide conformations to design radioligands with high affinity, selectivity, and favorable pharmacokinetics.
Opportunities
Rapid AI‑driven discovery can expand the radiopharmaceutical pipeline across multiple tumor targets, meeting growing demand for precision oncology agents.
Risk Factors
Regulatory hurdles for novel radioligands, technology execution risk, and competition from established radiopharmaceutical developers.
Competitive Landscape
Competes with companies like Novartis, Advanced Accelerator Applications, and emerging peptide‑radioligand startups; differentiation lies in AI‑enabled design speed and peptide cyclization technology.